Akeso shares plunge 31.8% after FDA rejects ivonescimab application
Published 2 d ago2 sourcesEvidence: Reported
The FDA declined Summit Therapeutics' application for ivonescimab, a cancer drug partnered with AstraZeneca. The rejection follows recent clinical collaboration agreements between the two firms, casting uncertainty over the drug's regulatory path and the partnership's near-term value.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 3 h ago1 sourceEvidence: Reported
Published 1 d ago11 sourcesEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 1 d ago6 sourcesEvidence: Reported